Georges Bou Nassif1, Chady Salloum2, Luca Paolino3, Daniel Azoulay2, Andrea Lazzati3. 1. Department of General Surgery, Center Hospitalier Intercommunal de Créteil, 40 Avenue de Verdun, 94000, Créteil, France. george.bn@hotmail.com. 2. Service de Chirurgie Digestive, Hépato-Biliaire, Hôpital Henri-Mondor - AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France. 3. Department of General Surgery, Center Hospitalier Intercommunal de Créteil, 40 Avenue de Verdun, 94000, Créteil, France.
Abstract
INTRODUCTION: The immunosuppressive therapy for life after liver transplantation (LT) is considered as a risk factor for obesity. Seven percent of the transplanted patients develop severe or morbid obesity. The obesity induces non-alcoholic steatohepatitis (NASH), which is a major risk factor for liver cirrhosis and hepatocellular carcinoma, without forgetting the cardiovascular risk and the devastating impact of obesity on quality of life of the transplanted patients. Consequently, obesity exposes these patients to future transplant loss. Bariatric surgery has been proposed for transplant patients to reduce the obesity-related comorbidities and to improve survival. We report in this video the surgical technique of laparoscopic sleeve gastrectomy (LSG) after LT. METHODS: We have performed between 2008 and 2017 the sleeve gastrectomy (SG) after LT in nine patients. Six procedures (66%) were performed totally by laparoscopy and three by upfront laparotomy. All the patients had a standard preoperative evaluation for obesity. All the procedures were assisted by a hepatic surgeon. Postoperatively patients were transferred to the liver ICU for 24 h then to the liver unit ward. RESULT: The median BMI was 41.9 kg/m2 (range 38-46.1 kg/m2). Median operative time was 120 min (range, 90-240 min). No intra-operative complications occurred. The median length of hospital stay was 7 days (range, 4-81 days). The postoperative course of the majority of the patients was uneventful except for one patient who develops a staple line leak. CONCLUSION: LSG after LT is technically feasible. Larger series are needed to improve the safety of the procedure in this high-risk population.
INTRODUCTION: The immunosuppressive therapy for life after liver transplantation (LT) is considered as a risk factor for obesity. Seven percent of the transplanted patients develop severe or morbid obesity. The obesity induces non-alcoholic steatohepatitis (NASH), which is a major risk factor for liver cirrhosis and hepatocellular carcinoma, without forgetting the cardiovascular risk and the devastating impact of obesity on quality of life of the transplanted patients. Consequently, obesity exposes these patients to future transplant loss. Bariatric surgery has been proposed for transplant patients to reduce the obesity-related comorbidities and to improve survival. We report in this video the surgical technique of laparoscopic sleeve gastrectomy (LSG) after LT. METHODS: We have performed between 2008 and 2017 the sleeve gastrectomy (SG) after LT in nine patients. Six procedures (66%) were performed totally by laparoscopy and three by upfront laparotomy. All the patients had a standard preoperative evaluation for obesity. All the procedures were assisted by a hepatic surgeon. Postoperatively patients were transferred to the liver ICU for 24 h then to the liver unit ward. RESULT: The median BMI was 41.9 kg/m2 (range 38-46.1 kg/m2). Median operative time was 120 min (range, 90-240 min). No intra-operative complications occurred. The median length of hospital stay was 7 days (range, 4-81 days). The postoperative course of the majority of the patients was uneventful except for one patient who develops a staple line leak. CONCLUSION: LSG after LT is technically feasible. Larger series are needed to improve the safety of the procedure in this high-risk population.
Authors: Jad Khoraki; Micah G Katz; Luke M Funk; Jacob A Greenberg; Luis A Fernandez; Guilherme M Campos Journal: Surg Obes Relat Dis Date: 2015-04-09 Impact factor: 4.734
Authors: Andrea Lazzati; Antonio Iannelli; Anne-Sophie Schneck; Anaïs Charles Nelson; Sandrine Katsahian; Jean Gugenheim; Daniel Azoulay Journal: Obes Surg Date: 2015-01 Impact factor: 4.129
Authors: Matthew Y C Lin; M Mehdi Tavakol; Ankit Sarin; Shadee M Amirkiai; Stanley J Rogers; Jonathan T Carter; Andrew M Posselt Journal: Surg Endosc Date: 2012-06-30 Impact factor: 4.584
Authors: Jean M Butte; Nicolás Devaud; Nicolás P Jarufe; Camilo Boza; Gustavo Pérez; Javiera Torres; Rosa M Pérez-Ayuso; Marco Arrese; Jorge Martínez Journal: Obes Surg Date: 2007-11 Impact factor: 4.129
Authors: J K Heimbach; K D S Watt; J J Poterucha; N Francisco Ziller; S D Cecco; M R Charlton; J E Hay; R H Wiesner; W Sanchez; C B Rosen; J M Swain Journal: Am J Transplant Date: 2012-11-08 Impact factor: 8.086
Authors: Víctor Lopez-Lopez; Juan José Ruiz-Manzanera; Dilmurodjon Eshmuminov; Kuno Lehmann; Marcel Schneider; Markus von der Groeben; David Ruiz de Angulo; Ursula Gajownik; Jose Antonio Pons; Francisco Sánchez-Bueno; Ricardo Robles-Campos; Pablo Ramírez-Romero Journal: Obes Surg Date: 2020-11-23 Impact factor: 4.129
Authors: John R Montgomery; Jordan A Cohen; Craig S Brown; Kyle H Sheetz; Grace F Chao; Seth A Waits; Dana A Telem Journal: Am J Transplant Date: 2020-05-08 Impact factor: 8.086